Benefit of Bevacizumab in Glioblastoma Under Discussion

This past year, ABC2 called upon the FDA, Genentech and the NCI’s Radiation Therapy Oncology Group, to harmonize the data generated in the various Avastin trials. 

Coordination between the groups would provide better data for the FDA as it considers final approval for the use of Avastin in treating GBM.  It would also provide better information for patients and physicians regarding the risks and benefits of using Avastin to treat GBM. 

This topic continues to draw a lot of attention in the field. 

Click HERE to read a recent article from Medscape discussing an article released in the February 20 issue of the New England Journal of Medicine on this topic.  ABC2’s petitioning of the FDA is noted.

 

 

 

Share |
June 17, 2015 09:46 AM
These studies provide a foundational rationale for ABC2's efforts in the profiling space.
June 4, 2015 01:18 PM
An ABC2-funded brain cancer vaccine receives positive reviews at the American Society of Clinical Oncology annual meeting.
May 31, 2015 01:58 PM
Our deepest sympathies go out to his friends and family. 

Join us in our fight for a cure!

Twitter